A randomized, placebo‐controlled crossover trial of phentermine‐topiramate ER in patients with binge‐eating disorder and bulimia nervosa | Zendy

Safer Debra L. | Zendy; Adler Sarah | Zendy; Sethi Shebani | Zendy; Bentley Jason P. | Zendy; Toyama Hannah | Zendy; Pajarito Sarah | Zendy; Najarian Thomas | Zendy

Premium

A randomized, placebo‐controlled crossover trial of phentermine‐topiramate ER in patients with binge‐eating disorder and bulimia nervosa

Author(s) -

Safer Debra L.,

Adler Sarah,

Sethi Shebani,

Bentley Jason P.,

Toyama Hannah,

Pajarito Sarah,

Najarian Thomas

Publication year - 2020

Publication title -

international journal of eating disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.785

H-Index - 138

eISSN - 1098-108X

pISSN - 0276-3478

DOI - 10.1002/eat.23192

Subject(s) - placebo , phentermine , binge eating , topiramate , crossover study , bulimia nervosa , binge eating disorder , abstinence , medicine , randomized controlled trial , psychology , gastroenterology , eating disorders , psychiatry , weight loss , obesity , alternative medicine , pathology , epilepsy

Open trials suggest phentermine/topiramate ER (PHEN/TPM-ER), food and drug administration (FDA) approved for obesity, has utility for binge eating. With no randomized controlled trials (RCTs) yet performed, this trial aimed to evaluate PHEN/TPM-ERs efficacy and safety in a crossover RCT for patients with binge-eating disorder (BED) or bulimia nervosa (BN).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research